ATE380189T1 - 2-amino-5-benzoylthiazol npy-antagonisten - Google Patents

2-amino-5-benzoylthiazol npy-antagonisten

Info

Publication number: ATE380189T1
Authority: AT; Austria
Prior art keywords: benzoylthiazole; amino; sup; npy antagonists; antagonists
Prior art date: 2003-08-12

Application number

AT04741359T

Other languages

English (en)

Inventor

Werner Neidhart

Matthias Nettekoven

Philippe Pflieger

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-08-12

Filing date

2004-08-04

Publication date

2007-12-15

2004-08-04 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2007-12-15 Application granted granted Critical

2007-12-15 Publication of ATE380189T1 publication Critical patent/ATE380189T1/de

Links

AJOABURBJQMQOP-UHFFFAOYSA-N (2-amino-1,3-thiazol-5-yl)-phenylmethanone Chemical compound S1C(N)=NC=C1C(=O)C1=CC=CC=C1 AJOABURBJQMQOP-UHFFFAOYSA-N 0.000 title 1
239000005557 antagonist Substances 0.000 title 1
101710151321 Melanostatin Proteins 0.000 abstract 1
102400000064 Neuropeptide Y Human genes 0.000 abstract 1
102100029549 Neuropeptide Y receptor type 5 Human genes 0.000 abstract 1
101710198055 Neuropeptide Y receptor type 5 Proteins 0.000 abstract 1
208000008589 Obesity Diseases 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
150000002148 esters Chemical class 0.000 abstract 1
URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 abstract 1
235000020824 obesity Nutrition 0.000 abstract 1
239000002464 receptor antagonist Substances 0.000 abstract 1
229940044551 receptor antagonist Drugs 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
150000007979 thiazole derivatives Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Diabetes (AREA)
Obesity (AREA)
Hematology (AREA)
Child & Adolescent Psychology (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Psychiatry (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Emergency Medicine (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Thiazole And Isothizaole Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT04741359T 2003-08-12 2004-08-04 2-amino-5-benzoylthiazol npy-antagonisten ATE380189T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP03017634		2003-08-12

Publications (1)

Publication Number	Publication Date
ATE380189T1 true ATE380189T1 (de)	2007-12-15

Family

ID=34130066

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04741359T ATE380189T1 (de)	2003-08-12	2004-08-04	2-amino-5-benzoylthiazol npy-antagonisten

Country Status (14)

Country	Link
US (1)	US7250431B2 (de)
EP (1)	EP1658288B1 (de)
JP (1)	JP2007501823A (de)
KR (1)	KR20060037435A (de)
CN (1)	CN100422179C (de)
AT (1)	ATE380189T1 (de)
AU (1)	AU2004263311A1 (de)
BR (1)	BRPI0413500A (de)
CA (1)	CA2533463A1 (de)
DE (1)	DE602004010529T2 (de)
ES (1)	ES2297437T3 (de)
MX (1)	MXPA06001570A (de)
RU (1)	RU2006107444A (de)
WO (1)	WO2005014592A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE102005000858A1 (de) *	2005-01-05	2006-07-20	Merck Patent Gmbh	Fluortenside
CA2634442A1 (en) *	2005-12-22	2007-07-05	Icagen, Inc.	Calcium channel antagonists
US8410284B2 (en)	2008-10-22	2013-04-02	Merck Sharp & Dohme Corp	Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2010051206A1 (en)	2008-10-31	2010-05-06	Merck Sharp & Dohme Corp.	Novel cyclic benzimidazole derivatives useful anti-diabetic agents
JP2013520502A (ja)	2010-02-25	2013-06-06	メルク・シャープ・エンド・ドーム・コーポレイション	有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
CA2826649C (en)	2011-02-25	2016-07-26	Merck Sharp & Dohme Corp.	Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
US20140045746A1 (en)	2012-08-02	2014-02-13	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
JP2016516004A (ja)	2013-02-22	2016-06-02	メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋＳｈａｒｐ＆ＤｏｈｍｅＣｏｒｐ．	抗糖尿病二環式化合物
WO2014139388A1 (en)	2013-03-14	2014-09-18	Merck Sharp & Dohme Corp.	Novel indole derivatives useful as anti-diabetic agents
WO2015051496A1 (en)	2013-10-08	2015-04-16	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
WO2018106518A1 (en)	2016-12-06	2018-06-14	Merck Sharp & Dohme Corp.	Antidiabetic heterocyclic compounds
WO2018118670A1 (en)	2016-12-20	2018-06-28	Merck Sharp & Dohme Corp.	Antidiabetic spirochroman compounds

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1247547A (en) *	1983-06-22	1988-12-28	Paul Hadvary	Leucine derivatives
US4844839A (en) *	1984-09-04	1989-07-04	Manchak Frank	In situ treatment and analysis of wastes
US4776409A (en) *	1984-09-04	1988-10-11	Manchak Frank	Insitu waste impoundment treating apparatus and method of using same
US5246960A (en) *	1984-12-21	1993-09-21	Hoffmann-La Roche Inc.	Oxetanones
CA1270837A (en) *	1984-12-21	1990-06-26	Hoffmann-La Roche Limited	Oxetanones
CA1328881C (en)	1984-12-21	1994-04-26	Pierre Barbier	Process for the manufacture of oxetanones
EP0235249B1 (de) *	1985-08-26	1992-12-23	MANCHAK, Frank, Jr.	Vorrichtung zur in-situ-behandlung von gefährlichem abfall und deren verwendung
CA2035972C (en)	1990-02-23	2006-07-11	Martin Karpf	Process for the preparation of oxetanones
US5274143A (en)	1991-07-23	1993-12-28	Hoffmann-La Roche Inc.	Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
US6004996A (en) *	1997-02-05	1999-12-21	Hoffman-La Roche Inc.	Tetrahydrolipstatin containing compositions
US6267952B1 (en)	1998-01-09	2001-07-31	Geltex Pharmaceuticals, Inc.	Lipase inhibiting polymers
DE19824175A1 (de) *	1998-05-29	1999-12-02	Novartis Ag	Amino-azol-Verbindungen
CA2340056C (en)	1998-08-14	2007-01-09	F. Hoffmann-La Roche Ag	Pharmaceutical compositions containing lipase inhibitors
PT1105123E (pt)	1998-08-14	2004-08-31	Hoffmann La Roche	Composicoes farmaceuticas contendo inibidores da lipase e quitosano
BR0308108A (pt) *	2002-02-28	2004-12-07	Hoffmann La Roche	Compostos; processo para a preparação de composto; composição farmacêutica que compreende o mesmo, utilização dos compostos e método de tratamento e profilaxia de enfermidades e de obesidade
AU2003253364B2 (en) *	2002-08-07	2007-06-07	F. Hoffmann-La Roche Ag	Thiazole derivatives

2004
- 2004-08-04 CA CA002533463A patent/CA2533463A1/en not_active Abandoned
- 2004-08-04 DE DE602004010529T patent/DE602004010529T2/de not_active Expired - Lifetime
- 2004-08-04 WO PCT/EP2004/008698 patent/WO2005014592A1/en not_active Ceased
- 2004-08-04 EP EP04741359A patent/EP1658288B1/de not_active Expired - Lifetime
- 2004-08-04 RU RU2006107444/04A patent/RU2006107444A/ru not_active Application Discontinuation
- 2004-08-04 AT AT04741359T patent/ATE380189T1/de not_active IP Right Cessation
- 2004-08-04 AU AU2004263311A patent/AU2004263311A1/en not_active Abandoned
- 2004-08-04 ES ES04741359T patent/ES2297437T3/es not_active Expired - Lifetime
- 2004-08-04 BR BRPI0413500-8A patent/BRPI0413500A/pt not_active IP Right Cessation
- 2004-08-04 KR KR1020067002829A patent/KR20060037435A/ko not_active Abandoned
- 2004-08-04 JP JP2006522949A patent/JP2007501823A/ja active Pending
- 2004-08-04 CN CNB2004800230173A patent/CN100422179C/zh not_active Expired - Fee Related
- 2004-08-04 MX MXPA06001570A patent/MXPA06001570A/es not_active Application Discontinuation
- 2004-08-10 US US10/915,199 patent/US7250431B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US7250431B2 (en)	2007-07-31
RU2006107444A (ru)	2007-09-20
BRPI0413500A (pt)	2006-10-10
JP2007501823A (ja)	2007-02-01
CA2533463A1 (en)	2005-02-17
KR20060037435A (ko)	2006-05-03
CN100422179C (zh)	2008-10-01
WO2005014592A1 (en)	2005-02-17
US20050038089A1 (en)	2005-02-17
EP1658288A1 (de)	2006-05-24
EP1658288B1 (de)	2007-12-05
DE602004010529T2 (de)	2008-11-27
AU2004263311A1 (en)	2005-02-17
ES2297437T3 (es)	2008-05-01
CN1852907A (zh)	2006-10-25
MXPA06001570A (es)	2006-05-15
DE602004010529D1 (de)	2008-01-17

Legal Events

Date	Code	Title	Description
2008-06-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
MY138941A (en)	2009-08-28	Aryl-pyridine derivatives
MX2009003939A (es)	2009-05-11	Derivados de imidazolona e imidazolidinona como inhibidores de la 11-beta-hidroxiesteroide deshidrogenasa de tipo 1 para diabetes.
NZ594597A (en)	2014-02-28	Substituted piperidines as ccr3 antagonists
ATE384058T1 (de)	2008-02-15	Thiazolderivate
ATE493386T1 (de)	2011-01-15	Trans-3-aza-bicyclo-ä3.1.0ü-hexan-derivate
MX2009004441A (es)	2009-05-22	Derivados de indazol utiles como inhibidores de las isoformas de higado.
NO20084853L (no)	2009-02-02	Forbindelser som er agonister av muscarinreseptorer og som kan vaere effektive i behandling av smerte, Alzheimers sykdom og/eller schizofreni
WO2007130075A8 (en)	2008-01-24	Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
TW200745032A (en)	2007-12-16	Novel heterobicyclic derivatives
NO20091409L (no)	2009-04-07	Pyridin-3-yl-derivater som immunmodulerende midler
MX2009014208A (es)	2010-01-28	Compuestos heterociclicos y usos de los mismos como inhibidores de erk.
TW200738241A (en)	2007-10-16	Pyridazine derivatives
IN2012DN03337A (de)	2015-10-23
ATE390922T1 (de)	2008-04-15	2-aminobenzothiazole als cb1 rezeptor inverse agonisten
MXPA04002338A (es)	2004-06-29	Derivados de carbazol y su uso como antagonistas receptores del npy5.
MX2010002584A (es)	2010-03-26	Derivados de piperidina como agonistas de receptores muscarinicos.
NO20085271L (no)	2009-01-06	Muscarin reseptoragonister som er effektive i behandling av smerte, Alzheimers sykdom og schizofreni
DE602004010529D1 (de)	2008-01-17	2-amino-5-benzoylthiazol npy-antagonisten
MX2010001020A (es)	2010-03-01	Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas.
GB0314967D0 (en)	2003-07-30	Piperazine derivatives
SG154443A1 (en)	2009-08-28	Piperidine derivatives as nk1 antagonists
TW200616976A (en)	2006-06-01	Pyrimidine derivatives
NO20075022L (no)	2007-10-04	(7-(2-(4-(3-trifluormetylfenyl)-1,2,3,6-tetrahydropyrid-1-yl)etyl) isokinolinbesylatsalt, fremstilling og terapeutiske anvendelser derav
TW200616958A (en)	2006-06-01	New alkyl-pyridines as 11-beta inhibitors for diabetes
IN2012DN01232A (de)	2015-05-15